Hilde Furberg
Director/Board Member bij SEDANA MEDICAL AB
Vermogen: 566 053 $ op 29-02-2024
Profiel
Hilde Furberg is SVP-Personalized Genetic Health Europe at Genzyme Europe BV and Partner at J&J Future Invest AS and on the board of 5 other companies.
In the past she occupied the position of Independent Non-Executive Director at BerGenBio ASA, Chairman of Blueprint Genetics Oy, Senior Vice President & European Head-Rare Disease at Genzyme Corp.
and General Manager of Baxter Medical AB.
She received a graduate degree from the University of Oslo.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
28-02-2023 | 53 199 ( 0.09% ) | 566 053 $ | 29-02-2024 |
Actieve functies van Hilde Furberg
Bedrijven | Functie | Begin |
---|---|---|
CALLIDITAS THERAPEUTICS AB | Director/Board Member | 01-12-2016 |
PCI BIOTECH HOLDING ASA | Director/Board Member | 01-05-2019 |
HERANTIS PHARMA OYJ | Director/Board Member | 15-04-2021 |
SEDANA MEDICAL AB | Director/Board Member | 01-01-2022 |
J&J Future Invest AS
J&J Future Invest AS Real Estate DevelopmentFinance J & J Future Invest AS is a Norwegian company that operates a real estate agency. | Corporate Officer/Principal | - |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Corporate Officer/Principal | 14-10-2011 |
Pluvia AS
Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | Director/Board Member | - |
Eerdere bekende functies van Hilde Furberg
Bedrijven | Functie | Einde |
---|---|---|
ONCOZENGE AB | Director/Board Member | 21-08-2023 |
BERGENBIO ASA | Chairman | 06-01-2017 |
░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Opleiding van Hilde Furberg
University of Oslo | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 8 |
---|---|
PROBI AB | Health Technology |
PCI BIOTECH HOLDING ASA | Health Technology |
CALLIDITAS THERAPEUTICS AB | Health Technology |
BERGENBIO ASA | Health Technology |
HERANTIS PHARMA OYJ | Health Technology |
COMBIGENE AB | Health Technology |
SEDANA MEDICAL AB | Health Technology |
ONCOZENGE AB | Health Technology |
Bedrijven in privébezit | 12 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Copenhagen Capacity
Copenhagen Capacity Financial ConglomeratesFinance Copenhagen Capacity provides investment promotion and economic development services. The private company is based in Copenhagen, Denmark. Asbjørn Overgaard Christiansen has been the CEO of the Danish company since 2020. | Finance |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | Health Technology |
Weifa ASA
Weifa ASA Pharmaceuticals: MajorHealth Technology Weifa ASA engages in the development, production and sales of medicines and other health products. Its products include medicines for pain relief, cough and cold, nutraceuticals, and dermatology. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway. | Health Technology |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Health Technology |
Baxter Medical AB | |
Blueprint Genetics Oy
Blueprint Genetics Oy BiotechnologyHealth Technology Blueprint Genetics Oy engages in the provision of genetic diagnostics and clinical interpretation of hereditary diseases. It offer dignistic tests for cardiology; dermatology; endocrinology; immunology; metabolic disorder; nephrology; and pulmonology. The company was founded by Tommi Pietari Lehtonen, Juha Koskenvuo, Tero-Pekka Alastalo, and Samuel Myllykangas in 2008 and is headquartered in Helsinki, Finland. | Health Technology |
Pluvia AS
Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | Commercial Services |
Bio-Me AS
Bio-Me AS BiotechnologyHealth Technology Bio-Me AS operates as a boi-tech firm. It researches and develops patented technologies and new approaches in bacteria analysis. The company is headquartered in Oslo, Norway. | Health Technology |
J&J Future Invest AS
J&J Future Invest AS Real Estate DevelopmentFinance J & J Future Invest AS is a Norwegian company that operates a real estate agency. | Finance |
Tappin AS | |
Algeta ASA
Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |